In February 2025, the Danish Health Data Authority opened the application period for changes to the 2027 DRG logic, including the creation of new DRG codes and modifications to the grouping logic for existing DRGs. The application deadline is October 31, 2025.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent study, Puñal-Riobóo et al. developed a standardized minimum outcome dataset for left ventricular assist device (LVAD) registries to address key evidence gaps and meet the needs of Health Technology Assessment (HTA) bodies and healthcare professionals. Building on prior HTA findings from EUnetHTA, the authors conducted a structured three-round Delphi process with an expert panel of cardiologists to assess the relevance of various outcome measures. The consensus resulted in 18 key outcomes and 47 variables across seven healthcare domains, strengthening the reliability of real-world evidence and supporting more informed clinical and policy decisions.

The French National Authority for Health (HAS) has released new recommendations about add-on reimbursement of medical devices and medical aids from the February 2025 meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Sixteen favorable opinions were published concerning the registration or modification of registration conditions/extension of indications for the medical devices in the List of Reimbursable Products and Services (LPPR). They relate to cardiovascular and peripheral vascular, neurovascular, endocrinology, interventional radiology, nephrology and urology, orthopedic devices, and medical aids.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Schweitzer et al. explored the suitability of the current German HTA dossier templates for the impending EU joint clinical assessment (JCA). The study examined how extensively safety endpoint and subgroup analyses in German dossiers were actually considered by IQWiG and the G-BA. The authors found that the current German HTA templates significantly increased the workload of HTA developers while leaving many reported outcomes unconsidered by IQWiG and G-BA. To mitigate duplicative efforts and ensure prompt availability of medicinal products in line with the EU HTA Regulation framework, the authors recommend well-defined dossier requirements, early consultations, and proactive engagement with HTA developers.

In late February 2025, the Innovation Committee at the Federal Joint Committee (G-BA) published the decision recommending the transfer to standard care for the completed project in the peripheral vascular field. The project was dedicated to the integration and spatial analysis of regional, site-specific, and patient-specific factors to improve the quality of care in carotid artery revascularization.

MTRC developed an analytical White Paper featuring the Health Economic Evidence Requirements for Medical Devices across the BIG5 European markets: England, France, Germany, Italy and Spain.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Value-based Publications Digest. In a recent publication, Otte et al. synthesized expert discussions on the challenges and opportunities of implementing Value-Based Healthcare and Health Technology Assessment in emerging markets.The study highlighted the importance of Real-World Evidence in biosimilar value assessment and decision-making processes. The authors proposed Multi-Criteria Decision Analysis as a tool for optimizing pharmaceutical procurement in resource-constrained settings. The findings emphasized the need for stronger interdisciplinary collaboration among stakeholders and the expansion of public-private partnerships to address healthcare access barriers and drive system-wide improvements.

In February 2025, SBRI Healthcare, funded by the NHS Accelerated Access Collaborative, announced the results of three competitions. Funding of £1.3m was allocated for the development of 14 innovations that support women’s health, £1m for the development of 11 innovations that improve infection prevention and control to mitigate the spread of antimicrobial resistance, and £3 million to support four innovations that improve the health and well-being of children and young people who have asthma, epilepsy, or diabetes.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Sustainability Publications Digest. In a recent publication, McCance et al. conducted a comparative carbon footprint analysis of disposable versus reusable surgical instruments in cataract surgery in the UK. Their findings highlighted the substantial environmental impact of single-use items, which had a 27-fold higher carbon footprint than reusable alternatives, with net carbon savings achieved after 19 or more reuses. These findings emphasize the necessity of integrating sustainability strategies into surgical workflows to mitigate healthcare's environmental footprint.

In January 2025, the General Directorate of the Common Package of Benefits of the National Health and Pharmacy System released a Resolution regarding the participation of patients in the working groups dependent on the Commission of Benefits, Insurance, and Financing (CPAF). This Resolution officially endorses patient involvement in CPAF working groups to enhance the legitimacy and inclusivity of healthcare policy decisions.

We are pleased to announce the expansion of our HEOR Department with the addition of Elizaveta Fedina, an experienced health economist with a strong background in health technology assessment (HTA) and economic evaluation.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Health Economic Publications Digest. In a recent publication, Donovan et al. conducted a qualitative interview study with 16 experts to investigate the gaps in capturing implementation costs within economic evaluations. The study revealed four key barriers: difficulties in defining, collecting, and valuing implementation costs; the lack of standardized methodologies; and the lack of multidisciplinary collaboration in enabling implementation costing. The authors advocated for standardized approaches to implementation cost estimation, emphasizing that improved methodologies could enhance confidence in economic assessments and better inform resource allocation.